ergoline and Genital-Diseases--Female

Topics: Adenoma; Adult; Diagnosis, Differential; Ergolines; Female; Follow-Up Studies; Galactorrhea; Genital Diseases, Female; Humans; Hypophysectomy; Hypothyroidism; Infertility, Female; Pergolide; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Sella Turcica; Tomography, X-Ray Computed; Visual Field Tests

The aim of this study was to compare the efficiency of dopamine agonist, Cabergoline, in decreasing the size of endometrioma, with that of luteinizing hormone releasing hormone (LHRH) agonist, triptorelin acetate.. This was a prospective, randomized study.. The setting was in two private medical centers in the UAE, from January 2011 to February 2012.. One hundred and forty patients complaining of endometrioma, and fulfilling the eligibility criteria, were chosen and divided into two groups as follows: Group I comprised 71 patients; all of them received Cabergoline tablets, 0.5 mg tablets, twice per week for 12 weeks. Group II comprised 69 patients; all of them received LHRH agonist, decapeptyl, 3.75 mg subcutaneous, single injection, once a month for 3 months. All patients underwent vaginal ultrasound before and after the treatment period to compare the change in the size of endometrioma by the same sonography team in each hospital that was blind to the treatment groups.. The outcome was measured by the changes in the endometrioma size by vaginal ultrasound after completion of the 3 months' treatment period. The management line was considered to be significantly effective if the endometrioma size was reduced by more than 25 % of its original pretreatment size.. Group I: 46 out of the 71 patients (64.7 %) had significant decrease in endometrioma size. Group II: 15 out of 69 patients (21.7 %) had significant decrease in endometrioma size. Paired t test to compare the means of the two groups was highly significant (p < 0.05) CONCLUSION: Cabergoline (dostinex) yields better results in decreasing the size of endometrioma, compared to LHRH-agonist by exerting antiangiogenic effects through vascular endothelial growth factor receptor-2 (VEGFR-2) inactivation. It has no major side effects, easier to administer, and cheaper than LHRH agonists.

Topics: Administration, Oral; Adult; Cabergoline; Dopamine Agonists; Endometriosis; Ergolines; Female; Genital Diseases, Female; Gonadotropin-Releasing Hormone; Humans; Injections, Subcutaneous; Luteolytic Agents; Magnetic Resonance Imaging; Prospective Studies; Triptorelin Pamoate; Ultrasonography

We assessed several classes of serotonergic drugs in order to evaluate whether they constitute a risk factor for hospitalization for bleeding (gastrointestinal, intracranial, or in the female genital tract). A case-control study was conducted using data from the PHARMO record linkage system (RLS). The study population comprised 28,289 cases and 50,786 matched controls. Current use of antidepressant drugs was associated with all three types of bleeding, whereas antipsychotic drugs were associated with an increased risk of gastrointestinal and intracranial bleeding. Current use of ergoline derivatives increased the risk of female genital tract bleeding. The risks of gastrointestinal and intracranial bleeding were higher in new users of antidepressant and antipsychotic drugs as compared with those who were already receiving these drugs. No clear association was found between the degree of affinity for the serotonin (5-HT) transporter or the 5-HT(2A) receptor and the risk of any of the three types of bleeding. The association between antipsychotic drugs and gastrointestinal bleeding may warrant further research, in view of the fact that this association was rather unexpected.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Case-Control Studies; Ergolines; Female; Gastrointestinal Hemorrhage; Genital Diseases, Female; Hemorrhage; Hospitalization; Humans; Intracranial Hemorrhages; Male; Medical Record Linkage; Middle Aged; Receptor, Serotonin, 5-HT2A; Risk Factors; Serotonin 5-HT2 Receptor Agonists; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins; Young Adult

Topics: Anti-Bacterial Agents; Antifungal Agents; Cabergoline; Carboprost; Clindamycin; Dopamine Agonists; Drug Combinations; Ergolines; Female; Fertility Agents, Female; Fluconazole; Genital Diseases, Female; Humans; Nafarelin; Pregnancy; Pregnancy Complications; Tromethamine